1) Cipla & Lupin numbers the following day
Pharma quarter to be in recognition as two large-cap players i.E Cipla & Lupin to claim Q3 consequences. The key to observing in each agency might be US income which can be expected to stabilize with a lower intensity of fee erosion & visibility on complex approvals the important thing. Credit Suisse Expect Lupin’s US sales to boom 7% QoQ to US$183 mn because of be
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
